U.S. Markets closed
  • S&P 500

    +8.70 (+0.24%)
  • Dow 30

    +37.90 (+0.13%)
  • Nasdaq

    +111.44 (+0.92%)
  • Russell 2000

    +10.25 (+0.56%)
  • Crude Oil

    -0.18 (-0.39%)
  • Gold

    -23.10 (-1.28%)
  • Silver

    -0.81 (-3.44%)

    +0.0057 (+0.4788%)
  • 10-Yr Bond

    -0.0360 (-4.10%)
  • Vix

    -0.41 (-1.93%)

    -0.0042 (-0.3169%)

    -0.1650 (-0.1583%)

    +579.68 (+3.37%)
  • CMC Crypto 200

    -4.23 (-1.25%)
  • FTSE 100

    +4.65 (+0.07%)
  • Nikkei 225

    +107.40 (+0.40%)

Infinity Initiates 2 Studies for Lead Candidate IPI-549

Zacks Equity Research

Infinity Pharmaceuticals Inc. INFI has announced the initiation of two studies for its lead pipeline candidate-IPI-549, a first-in-class, oral immuno-oncology product candidate that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.

Shares of the company have increased 2.6% compared with the industry’s growth of 6.5%.

The company initiated a phase II, MARIO-3 study in collaboration with Roche AG RHHBY, evaluating IPI-549 in combination with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC), and in combination with Tecentriq. We note that, the combination of Tecentriq plus Abraxane is approved for TNBC. MARIO-3 is evaluating the addition of PI-549 to this regimen in both PDL1+ and PDL1- front-line TNBC patients.  MARIO-3 also includes a cohort evaluating IPI-549 in combination with Tecentriq and Avastin (bevacizumab) in front-line PDL1+ and PDL1- renal cell cancer (RCC) patients.

Separately, Arcus Biosciences RCUS has initiated a phase I/Ib study, in collaboration with Infinity, evaluating IPI-549 in a combination regimen with AB298, Arcus's dual adenosine receptor antagonist, and Doxil, a chemotherapy, in patients with advanced TNBC.

By partnering with leading pharmaceutical and biotech companies, Infinity is evaluating IPI-549 for various diseases.  The company has a collaboration agreement with Bristol Myers BMY to evaluate its lead pipeline candidate IPI-549 with the latter’s PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company expects to complete enrollment in the second half of 2019 in the expanded combination cohorts in MARIO-1, an ongoing phase I/Ib study of IPI-549 as a monotherapy, and in combination with Opdivo in approximately 220 patients with advanced solid tumors.

Infinity currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Infinity Pharmaceuticals, Inc. Price


Infinity Pharmaceuticals, Inc. Price
Infinity Pharmaceuticals, Inc. Price

Infinity Pharmaceuticals, Inc. price | Infinity Pharmaceuticals, Inc. Quote

It’s Illegal in 42 States, But Investors Will Make Billions Legally

In addition to the companies you read about above, today you get details on the newly-legalized industry that’s tapping into a “habit” that Americans spend an estimated $150 billion on every year. That’s twice as much as they spend on marijuana, legally or otherwise. Zacks special report revealing how investors can profit from this new opportunity. As more states legalize this activity, the industry could expand by as much as 15X. Zacks’ has just released a Special Report revealing 5 top stocks to watch in this space.

See these 5 “sin stocks” now>>           

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
Roche Holding AG (RHHBY) : Free Stock Analysis Report
Infinity Pharmaceuticals, Inc. (INFI) : Free Stock Analysis Report
Arcus Biosciences, Inc. (RCUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research